A combination clinical study of G1T48/lerociclib regimen for ER+, HER2- breast cancer
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2019
Price : $35 *
At a glance
- Drugs G1T-48 (Primary) ; Lerociclib (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors G1 Therapeutics
- 29 Sep 2019 According to a G1 Therapeutics media release, based on safety and tolerability findings in the Phase 1b portion of this trial, the company selected the 600 mg and 1,000 mg doses of G1T48 for evaluation in the ongoing Phase 2a portion and will use these data to select the dose for the pivotal trial.
- 07 Aug 2019 According to a media release, the company is planning to initiate this study in 2020.
- 24 Aug 2018 New trial record